Modified Psilocin Compounds Show Promise for Reducing Hallucinations in Therapy

The landscape of mental health treatment may be on the cusp of a significant shift. Researchers are reporting progress in developing a modified form of psilocybin – the active compound in “magic mushrooms” – that appears to offer therapeutic benefits for conditions like depression, potentially without the hallucinogenic effects traditionally associated with the substance. This development, published in ACS’ Journal of Medicinal Chemistry, could broaden access to a promising treatment avenue for those who might otherwise be hesitant due to the psychedelic experience.

Understanding Psilocybin and its Potential

Psilocybin has garnered increasing scientific attention in recent years for its potential to treat a range of neuropsychiatric conditions, including depression, anxiety, substance use disorders, and even certain neurodegenerative diseases. Although, the powerful hallucinogenic effects have presented a significant hurdle to wider clinical adoption. These effects, while sometimes considered a part of the therapeutic process by some practitioners, can be distressing for patients and create logistical challenges for treatment settings. The core idea behind this new research is to separate the therapeutic benefits from the mind-altering experience.

The key lies in psilocin, the active form of psilocybin once it’s processed by the body. Researchers, led by teams at MGGM Therapeutics, LLC, and NeuroArbor Therapeutics Inc., focused on engineering modified versions of psilocin. Their goal was to create molecules that would still interact with key serotonin pathways in the brain – pathways heavily implicated in mood regulation – but with a reduced capacity to trigger hallucinations. Serotonin, a neurotransmitter, plays a crucial role in regulating mood, sleep, appetite, and other essential brain functions. Disruptions in serotonin signaling are often observed in individuals with mood disorders and neurodegenerative conditions like Alzheimer’s disease. The American Chemical Society highlights the growing scientific perspective that the beneficial effects of psychedelics and their hallucinogenic properties may not be inextricably linked.

Engineering a Less Psychedelic Psilocin

The research team designed five chemical variants of psilocin, focusing on altering how the molecules are absorbed and released into the brain. The aim was to achieve a slower, more sustained release of psilocin, potentially minimizing the peak concentrations that contribute to hallucinogenic effects. One compound, designated 4e, emerged as the most promising candidate. Laboratory tests using human plasma and simulated gastrointestinal conditions showed that 4e was stable during absorption and released psilocin gradually.

Crucially, 4e maintained its ability to activate key serotonin receptors at levels comparable to those of pharmaceutical-grade psilocybin. This suggests that the modified molecule could still exert the desired therapeutic effects on brain signaling. To further investigate, the researchers conducted a study in mice, comparing the effects of 4e and standard psilocybin when administered orally. They tracked the amount of psilocin reaching the bloodstream and brain over a 48-hour period.

Promising Results in Animal Studies

The results showed that 4e efficiently crossed the blood-brain barrier, but produced a lower, yet longer-lasting, level of psilocin in the brain compared to psilocybin. This slower release profile appeared to translate into a significant reduction in psychedelic-like activity. Scientists measured this activity by observing “head twitches” in the mice – a well-established indicator of psychedelic effects in rodents. Mice treated with 4e exhibited significantly fewer head twitches than those given psilocybin, even though 4e was still interacting strongly with serotonin receptors. Medical Xpress reports that the researchers believe this difference is primarily due to the rate and amount of psilocin released in the brain.

What This Means for Future Treatments

These findings suggest that it may be possible to develop stable, psilocin-based compounds that can effectively target serotonin receptors in the brain while minimizing the intense, mind-altering effects often associated with psychedelics. This could pave the way for a new generation of therapeutics for depression and other brain disorders, potentially making these treatments more accessible and acceptable to a wider range of patients. However, it’s crucial to emphasize that this research is still in its early stages. The study was conducted in mice, and further research is needed to confirm these findings in humans.

Andrea Mattarei, a corresponding author of the study, notes that the findings are “consistent with a growing scientific perspective suggesting that psychedelic effects and serotonergic activity may be dissociated.” This dissociation opens the door to designing new treatments that retain the beneficial biological activity while reducing unwanted hallucinogenic responses, potentially leading to safer and more practical treatment strategies.

The Path Forward: Clinical Trials and Further Research

The researchers acknowledge funding from MGGM Therapeutics, LLC, and NeuroArbor Therapeutics Inc., and several authors have patents related to psilocin. This funding and patent situation doesn’t invalidate the research, but it’s important to be aware of potential conflicts of interest. ScienceDaily reports that the next steps involve more comprehensive studies to fully understand how these modified psilocin molecules work and to assess their overall biological impact. Before these compounds can be evaluated for safety and therapeutic potential in humans, rigorous preclinical testing is essential.

the goal is to determine whether these modified psilocin derivatives can provide the therapeutic benefits of psilocybin without the challenging side effects, offering a new hope for individuals struggling with treatment-resistant depression and other mental health conditions. The development of such a treatment would require extensive clinical trials to demonstrate efficacy and safety, a process that could take several years. Public health agencies will likely monitor the progress of this research closely, and guidance for clinicians and patients will evolve as more data grow available.